Tarsus Pharmaceuticals, Inc.
TARS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$68.20
KIRA · Stoqly’s AI analyst, in plain words
- Tarsus Pharmaceuticals, Inc. had $451M of revenue in fiscal 2025, up 146.7% on the year before.
- Its operating margin was −15.7%, up 50.2 pts: of every 100 in sales, about −16 is left after running the business.
- Tarsus Pharmaceuticals, Inc. lost $66.4M in fiscal 2025.
- Free cash flow was −$22.3M in fiscal 2025, −4.9% of revenue.
- Tarsus Pharmaceuticals, Inc. has $345M more cash than debt.
Market cap
$3.0B
P/E
—
Revenue
$451M
Net income
−$66.4M
Free cash flow
−$22.3M
Operating margin
−15.7%
Tarsus Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+146.7%
Yes. Sales grew 146.7% last year.
Does it make a profit?
−14.7%
No. It lost money last year.
Does profit turn into cash?
−4.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tarsus Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- Tarsus Pharmaceuticals, Inc.
- CIK
- 0001819790
Tarsus Pharmaceuticals, Inc. · TARS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $57.0M | $25.8M | $17.4M | $183M | $451M |
| Revenue growth | — | −54.7% | −32.4% | 948.6% | 146.7% |
| Operating margin | −21.3% | −242.9% | −820.5% | −65.9% | −15.7% |
| Net income | −$13.8M | −$62.1M | −$136M | −$116M | −$66.4M |
| Net margin | −24.2% | −240.5% | −778.9% | −63.2% | −14.7% |
| Diluted EPS | −$0.67 | −$2.52 | −$4.62 | −$3.07 | −$1.59 |
| Cash | |||||
| Cash from operations | $3.7M | −$49.0M | −$117M | −$83.0M | −$12.5M |
| Capital expenditure | $0.6M | $0.5M | $1.5M | $1.6M | $9.9M |
| Free cash flow | $3.2M | −$49.5M | −$119M | −$84.6M | −$22.3M |
| FCF margin | 5.5% | −191.9% | −682.0% | −46.2% | −4.9% |
| Share count change | 231.1% | 19.8% | 19.3% | 28.0% | 11.1% |
| Debt and strength | |||||
| Cash and short-term investments | $172M | $217M | $227M | $291M | $417M |
| Debt incl. finance leases | $0.0M | $19.4M | $29.8M | $71.8M | $72.4M |
| Shareholders' equity | $167M | $193M | $197M | $225M | $343M |
| Current ratio | 15.3x | 14.6x | 6.9x | 4.4x | 3.9x |
| Interest coverage | — | −28.5x | −42.8x | −15.4x | −7.9x |
| Returns and quality | |||||
| Return on capital | — | — | — | −1,903.5% | — |
| Return on equity | −8.3% | −34.5% | −69.7% | −54.8% | −23.4% |
| Return on tangible equity | −8.3% | −32.2% | −70.4% | −53.4% | −19.8% |
| Piotroski F-score | 4 | 1 | 1 | 3 | 4 |
| Altman Z'' | 19.1 | 8.4 | 1.8 | 1.1 | 2.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$20.0M
9 insiders
Of sales under plans
64%
$12.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tarsus Pharmaceuticals, Inc. · TARS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $68.20 a share, the company is worth $3.0B.
Source: SEC EDGAR XBRL filings (CIK 0001819790). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.